The U.S. pharmaceutical sector is the largest in the world, valued at around $446 billion in 2016. While pharma and biopharma are significant for the U.S. economy, companies and their stocks can often be a roller coaster ride full of ups, downs, twists, and turns as dynamics and drug innovations comprehensively influence the pharma sector. Every day, news wires are full of press releases from these companies outlining the results of clinical trials conducted on new and experimental drugs and compounds. Pharma has also been a target of politicians in the United States, specifically in the Trump Administration as regulators seek to lower the cost of drugs and cap unfair revenues.